English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  50718375    Online Users :  457
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"ou d l"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 41-50 of 103  (11 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-08-31T06:29:34Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:32Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:25Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-11T03:46:42Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏 2021-08-11T03:46:38Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2021-05-02T03:56:41Z Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer Ou D.-L.; Tseng S.-J.; Kempson I.M.; Hsu C.-L.; PAN-CHYR YANG; Liao Z.-X.
臺大學術典藏 2021-03-15T07:59:42Z MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine Lu J.-W.;Lin Y.-M.;Lai Y.-L.;Chen C.-Y.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Lin Y.-M.; Lai Y.-L.; Chen C.-Y.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏 2021-03-15T07:59:41Z Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations—possible therapeutic efficacy of cabozantinib Ko Y.-C.;Chung-Yi Hu;Liu Z.-H.;Tien H.-F.;Ou D.-L.;Chien H.-F.;Lin L.-I.; Ko Y.-C.; CHUNG-YI HU; Liu Z.-H.; Tien H.-F.; Ou D.-L.; Chien H.-F.; Lin L.-I.
臺大學術典藏 2021-03-15T07:59:41Z Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD) Lu J.-W.;Wang A.-N.;Liao H.-A.;Chen C.-Y.;Hou H.-A.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Wang A.-N.; Liao H.-A.; Chen C.-Y.; Hou H.-A.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏 2021-03-09T05:18:38Z Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma Ou D.-L.; Ying-Chun Shen; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L.

Showing items 41-50 of 103  (11 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page